09
Jun
FDA Starts Push for Transparency in Fulfilling Their 2018 Compounding Policy Priorities Plan Image

Compounding Guidance Finalized by FDA

With much activity still surrounding compounding pharmacies and outsourcing facilities, and with enforcement action still on the rise, today FDA issued two final Guidance documents that describe the types of bulk drug substances that can be used for compounding for section 503A (pharmacies) and 503B (outsourcing facilities) without FDA enforcement action.  This also obviously assumes […]

Read More
09
Jun

Ricki A. Chase, New Director, Compliance Practice at Lachman Consultant Services, Inc.

We are pleased to announce that Ricki A. Chase will join Lachman Consultants as a Director in the Compliance Practice, effective June 20, 2016. Ricki Chase comes to Lachman Consultants after an impressive 16-year career, culminating as Director, Investigations Branch at the U.S. Food and Drug Administration where she was responsible for all operations of […]

Read More
06
Jun
OGD Updates Additional Metrics In March Stats Image

May Monthly ANDA Approval Information – But the Wait is On!

Information on the FDA’s Monthly Approval Report (here)  is usually not complete.  Typically, there may be up to a 5-10% discrepancy (lower than actual) in the numbers of Approvals and Tentative Approvals reported.  The discrepancy improves over time but seldom do the numbers actually match the reported number of approval actions on the Activities Report […]

Read More
1 2